Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males, greater than or equal to (\>=) 12 years of age.~* Severe hemophilia A or B with inhibitors.~  * (Severity confirmed by a central laboratory where coagulation factor VIII (FVIII) level was less than (\<)1% or factor IX (FIX) level was less than or equal to \[\<=\]2% at Screening; Inhibitors defined as inhibitor titer of \>=0.6 Bethesda units per milliliter \[BU/mL\] or as evidenced by medical records).~* A minimum of 6 bleeding episodes requiring BPA treatment within the last 6 months prior to screening.~* Willing and able to comply with the study requirements and to provide written informed consent and assent.~Exclusion Criteria:~* Known co-existing bleeding disorders other than hemophilia A or B.~* Antithrombin (AT) activity \<60% at Screening.~* Co-existing thrombophilic disorder.~* Clinically significant liver disease.~* Active hepatitis C virus infection.~* HIV positive with a cluster of differentiation-4 count of \<200 cells/microliter.~* History of arterial or venous thromboembolism.~* Inadequate renal function.~* History of multiple drug allergies or history of allergic reaction to an oligonucleotide or N-Acetylgalactosamine.~* History of intolerance to SC injection(s).~* Any other conditions or comorbidities that would make the participant unsuitable for enrollment or could interfere with participation in or completion of the study, per Investigator judgement.

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bypassing Agents (BPA) On-demand (Type: ACTIVE_COMPARATOR): Participants received On-demand BPAs (use of these agents, as needed, for episodic bleeding episodes, and not on a regular regimen intended to prevent spontaneous bleeding) per Investigator discretion from Day 1 for treatment of breakthrough bleeding episodes, up to a total of 9 months.
- Fitusiran 80 mg Prophylaxis (Type: EXPERIMENTAL): Participants received Fitusiran 80 mg subcutaneously (SC) as prophylaxis once monthly from Day 1, along with the on-demand BPAs (per investigator's discretion and within bleeding dosing guidelines) for treatment of breakthrough bleeding episodes, up to a total of 9 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).